Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS

Launched by ZHUJIANG HOSPITAL · Mar 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to monitor patients with liver cancer (hepatocellular carcinoma) after they have had surgery to remove the tumor. The researchers want to see if testing for certain cancer cells in the blood (called circulating tumor cells or CTCs) can help predict if the cancer will come back earlier than traditional imaging methods like scans. By doing this, they hope to find better ways to manage treatment after surgery, which could lead to more personalized care for patients.

To participate in the trial, patients need to be between 18 and 75 years old and have been diagnosed with early-stage liver cancer that can be surgically removed. They should not have received any cancer treatment before joining the trial and must be in good physical health. If eligible, participants will provide blood samples for testing and will be monitored closely to see how well this new method works in predicting cancer recurrence. This trial aims to improve early diagnosis and treatment strategies for liver cancer survivors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female patients aged 18-75 years;
• • 2. Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0 /stage A/stage B, eligible for radical surgery;
• • 3. ECOG physical status score is 0-1;
• • 4. Child-Pugh score is 5-6 points (Level A);
• • 5. Not received any anti-tumor therapy;
• • 6. Laboratory tests were at normal levels within 7 days before enrollment.
• Exclusion Criteria:
• • 1. Patient can't provide blood samples for CTCs and CTC-DNA testing;
• • 2. Patient with two or more types of tumors at the same time;
• • 3. Non-primary liver lesions;
• • 4. Pregnant or lactating women;
• • 5. Patient with a history of other malignant tumors within the past 5 years or at the same time, except cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid papillary carcinoma;
• • 6. Patient with serious heart disease;
• • 7. Other conditions deemed unsuitable for inclusion by the researcher.